China Universal Asset Management Company’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

China Universal Asset Management Company’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-433	Closed	-$44.1K	–	460
2023 Q2	$44.1K	Sell	433 -2	-0.5%	-$189	0.01%	205
2023 Q1	$39.5K	Buy	435 +112	+35%	+$6.57K	0.01%	167
2022 Q4	$12.3K	Buy	323 +28	+9%	+$964	﹤0.01%	209
2022 Q3	$7K	Buy	+295	New	+$8.18K	﹤0.01%	242

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

China Universal Asset Management Company's RETA Position: Q3 2023 in Review

China Universal Asset Management Company sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 433 shares — an estimated $44.1K sold.

China Universal Asset Management Company first reported a position in RETA in Q3 2022 and held it in 4 quarters. The position peaked at $44.1K in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

China Universal Asset Management Company reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
China Universal Asset Management Company sold 433 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $44.1K.
China Universal Asset Management Company first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2022 and held it in 4 quarters.
China Universal Asset Management Company's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $44.1K in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on China Universal Asset Management Company's 13F filing for Q3 2023, filed 31 Oct 2023.